Biohaven Pharmaceutical Valuation
| BHVN Stock | USD 29.87 1.17 3.77% |
At this time, the firm appears to be overvalued. Biohaven Pharmaceutical shows a prevailing Real Value of $28.25 per share. The current price of the firm is $29.87. Our model approximates the value of Biohaven Pharmaceutical from analyzing the firm fundamentals such as Current Valuation of 2.72 B, shares owned by insiders of 11.55 %, and Return On Equity of -1.99 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Biohaven Pharmaceutical's price fluctuation is not too volatile at this time. Calculation of the real value of Biohaven Pharmaceutical is based on 3 months time horizon. Increasing Biohaven Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biohaven Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biohaven Stock. However, Biohaven Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 29.87 | Real 28.25 | Hype 29.87 | Naive 33.98 |
The intrinsic value of Biohaven Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biohaven Pharmaceutical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biohaven Pharmaceutical Holding helps investors to forecast how Biohaven stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biohaven Pharmaceutical more accurately as focusing exclusively on Biohaven Pharmaceutical's fundamentals will not take into account other important factors: Biohaven Pharmaceutical Total Value Analysis
Biohaven Pharmaceutical Holding is currently anticipated to have valuation of 2.72 B with market capitalization of 3.17 B, debt of 32.78 M, and cash on hands of 23.21 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biohaven Pharmaceutical fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.72 B | 3.17 B | 32.78 M | 23.21 M |
Biohaven Pharmaceutical Asset Utilization
One of the ways to look at asset utilization of Biohaven is to check how much profit was generated for every dollar of assets it reports. Biohaven Pharmaceutical Holding shows a negative utilization of assets of -0.97 percent, losing $0.009685 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Biohaven Pharmaceutical Holding shows how discouraging it operates for each dollar spent on its assets.Biohaven Pharmaceutical Ownership Allocation
Biohaven Pharmaceutical holds a total of 102.06 Million outstanding shares. The majority of Biohaven Pharmaceutical Holding outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biohaven Pharmaceutical to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biohaven Pharmaceutical. Please pay attention to any change in the institutional holdings of Biohaven Pharmaceutical Holding as this could imply that something significant has changed or is about to change at the company. Also note that nearly three million four hundred nineteen thousand one hundred seventy-seven invesors are currently shorting Biohaven Pharmaceutical expressing very little confidence in its future performance.Biohaven Pharmaceutical Profitability Analysis
Net Loss for the year was (846.42 M) with profit before overhead, payroll, taxes, and interest of 0.About Biohaven Pharmaceutical Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Biohaven Pharmaceutical Holding. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Biohaven Pharmaceutical based exclusively on its fundamental and basic technical indicators. By analyzing Biohaven Pharmaceutical's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Biohaven Pharmaceutical's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biohaven Pharmaceutical. We calculate exposure to Biohaven Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biohaven Pharmaceutical's related companies.Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. Biohaven is traded on New York Stock Exchange in the United States.
Biohaven Pharmaceutical Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 91.2 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.